Antiphospholipid syndrome secondary prevention
|
Antiphospholipid syndrome Microchapters |
|
Differentiating Antiphospholipid syndrome from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Antiphospholipid syndrome secondary prevention On the Web |
|
American Roentgen Ray Society Images of Antiphospholipid syndrome secondary prevention |
|
Risk calculators and risk factors for Antiphospholipid syndrome secondary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief:
Overview
Secondary Prevention
Randomized controlled trials have addressed the secondary prevention of thromboses. These trials showed:
A systematic review has summarized the research.[3]
References
- ↑ Crowther MA, Ginsberg JS, Julian J, Denburg J, Hirsh J, Douketis J; et al. (2003). "A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome". N Engl J Med. 349 (12): 1133–8. doi:10.1056/NEJMoa035241. PMID 13679527. Review in: ACP J Club. 2004 Mar-Apr;140(2):38
- ↑ Finazzi G, Marchioli R, Brancaccio V, Schinco P, Wisloff F, Musial J; et al. (2005). "A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS)". J Thromb Haemost. 3 (5): 848–53. doi:10.1111/j.1538-7836.2005.01340.x. PMID 15869575.
- ↑ Ruiz-Irastorza G, Hunt BJ, Khamashta MA (2007). "A systematic review of secondary thromboprophylaxis in patients with antiphospholipid antibodies". Arthritis Rheum. 57 (8): 1487–95. doi:10.1002/art.23109. PMID 18050167.